Stevanato Group/$STVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stevanato Group
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Ticker
$STVN
Sector
Primary listing
NYSE
Employees
5,521
Headquarters
Piombino Dese, Italy
Website
Stevanato Group Metrics
BasicAdvanced
$7.2B
45.52
$0.58
0.55
$0.06
0.24%
Price and volume
Market cap
$7.2B
Beta
0.55
52-week high
$28.00
52-week low
$17.12
Average daily volume
412K
Dividend rate
$0.06
Financial strength
Current ratio
1.787
Quick ratio
1.216
Long term debt to equity
24.511
Total debt to equity
29.916
Dividend payout ratio (TTM)
10.74%
Interest coverage (TTM)
24.73%
Profitability
EBITDA (TTM)
303.915
Gross margin (TTM)
28.33%
Net profit margin (TTM)
11.75%
Operating margin (TTM)
16.53%
Effective tax rate (TTM)
25.11%
Revenue per employee (TTM)
$247,350
Management effectiveness
Return on assets (TTM)
5.29%
Return on equity (TTM)
9.89%
Valuation
Price to earnings (TTM)
45.524
Price to revenue (TTM)
5.307
Price to book
5.12
Price to tangible book (TTM)
5.45
Price to free cash flow (TTM)
-94.657
Free cash flow yield (TTM)
-1.06%
Free cash flow per share (TTM)
-0.277
Dividend yield (TTM)
0.24%
Forward dividend yield
0.24%
Growth
Revenue change (TTM)
5.28%
Earnings per share change (TTM)
6.78%
3-year revenue growth (CAGR)
8.62%
3-year earnings per share growth (CAGR)
2.11%
3-year dividend per share growth (CAGR)
1.92%
What the Analysts think about Stevanato Group
Analyst ratings (Buy, Hold, Sell) for Stevanato Group stock.
Bulls say / Bears say
Revenue grew 7.9% year-over-year to €280.0 million, beating analyst expectations of €268.3 million and pointing to strong underlying demand (Reuters).
Wall Street holds a "buy" consensus with a median 12-month price target of $28.00, suggesting about 8.6% upside from current prices (Reuters).
In July, the group secured €200 million in new financing arrangements with BNL BNP Paribas, CDP, and Banco BPM to fund capacity expansions in Italy and the U.S., supporting its long-term growth initiatives (Contract Pharma).
Engineering segment revenue fell 2% to €36.5 million and reported a negative operating profit margin of 0.8%, illustrating challenges related to project timing and mix (Investing.com).
Free cash flow was negative €13 million in Q2, despite improving year-over-year, due to heavy capital expenditures of €60.3 million (Investing.com).
Net debt reached €312.4 million, compared to €94.2 million in cash, resulting in a leveraged balance sheet before major expansion investments (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Stevanato Group Financial Performance
Revenues and expenses
Stevanato Group Earnings Performance
Company profitability
Stevanato Group News
AllArticlesVideos
Stevanato Group to Participate in Upcoming Investor Conferences
Business Wire2 weeks ago
Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025
Business Wire1 month ago
Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stevanato Group stock?
Stevanato Group (STVN) has a market cap of $7.2B as of September 16, 2025.
What is the P/E ratio for Stevanato Group stock?
The price to earnings (P/E) ratio for Stevanato Group (STVN) stock is 45.52 as of September 16, 2025.
Does Stevanato Group stock pay dividends?
Yes, the Stevanato Group (STVN) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is $0.06263 and the yield is 0.24%. Stevanato Group has a payout ratio of 10.74% on a trailing twelve-month basis.
When is the next Stevanato Group dividend payment date?
The next Stevanato Group (STVN) dividend payment date is unconfirmed.
What is the beta indicator for Stevanato Group?
Stevanato Group (STVN) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.